Drug intelligence / Profile preview

Naoxueping

Development stage: Unknown
Lead developer: Xuanwu Hospital
Administration: Oral

Overview

Naoxueping is a traditional Chinese medicine (TCM) preparation developed by Xuanwu Hospital of Capital Medical University for the treatment of acute intracerebral hemorrhage (ICH). It is specifically utilized in the management of spontaneous, non-surgical ICH to facilitate the absorption of intracranial hematomas and reduce perihematomal brain edema. The preparation is typically administered as an adjunct to guideline-recommended standard treatments to enhance neurological recovery and improve clinical outcomes. As a botanical-based therapy, its pharmacological profile involves multi-target modulation of the inflammatory response and vascular integrity following a hemorrhagic event.

Brand names: Naoxueping
Other names: Naoxueping oral liquidNaoxueping decoction

Targets

AQP4 (Aquaporin-4)CD36 (CD36 antigen)F2 (Thrombin)TJP1 (Tight junction protein 1 (ZO-1))

Beyond the preview

Go deeper on Naoxueping.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Naoxueping.